Filtered By:
Cancer: Cancer
Vaccination: Malaria Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 40 results found since Jan 2013.
Sporozoite immunization: Innovative Translational Science to Support the Fight against malaria
Expert Rev Vaccines. 2023 Aug 11. doi: 10.1080/14760584.2023.2245890. Online ahead of print.ABSTRACTINTRODUCTION: Malaria, a devastating febrile illness caused by protozoan parasites, sickened 247,000,000 people in 2021 and killed 619,000, mostly children and pregnant women in sub-Saharan Africa. A highly effective vaccine is urgently needed, especially for Plasmodium falciparum (Pf), the deadliest human malaria parasite.AREAS COVERED: Sporozoites (SPZ), the parasite stage transmitted by Anopheles mosquitoes to humans, are the only vaccine immunogen achieving > 90% efficacy against Pf infection. This review describes &g...
Source: Cancer Control - August 12, 2023 Category: Cancer & Oncology Authors: Thomas L Richie L W Preston Church Tooba Murshedkar Peter F Billingsley Eric R James Mei-Chun Chen Yonas Abebe None Natasha Kc Sumana Chakravarty David Dolberg Sara A Healy Halimatou Diawara Mahamadou S Sissoko Issaka Sagara David M Cook Judith E Epstein Source Type: research
Biomimetic Nanovaccines: a Novel Approach in Immunization
Curr Pharm Des. 2023 May 29. doi: 10.2174/1381612829666230529094128. Online ahead of print.ABSTRACTAs the World Health Organization (WHO) declared, vaccines prevent an average of 2-3 million deaths yearly from diseases. However, effective prophylactic and therapeutic vaccines have yet to be developed for eradicating the deadliest diseases, viz., types of cancer, malaria, human immunodeficiency virus (HIV), and most serious microbial infections. Furthermore, scores of the existing vaccines have disadvantages, such as failure to completely stimulate the immune system, in vivo instability, high toxicity, need for the cold cha...
Source: Current Pharmaceutical Design - May 31, 2023 Category: Drugs & Pharmacology Authors: Javad Yaghmoorian Khojini Benjamin Babaei Maryam Shakarami Mahdis Mofidi Zahra Tahershamsi Tahura Fayeghi Arjmand Amir Tajbakhsh Seyed Mohammad Gheibihayat Source Type: research
Extracellular Vesicles derived from Plasmodium-infected Hosts as Stimuli of ''Trained'' Innate Immunity
Curr Med Chem. 2023 Feb 7. doi: 10.2174/0929867330666230207115157. Online ahead of print.ABSTRACTAlthough the burden of malaria has been successfully controlled globally, this disease remains a major public health issue. To date, neither existing drugs nor vaccines against malaria are sufficient in eliminating malaria worldwide. To achieve the eradication of malaria by 2040, effective interventions targeting all Plasmodium species are urgently needed. As the cornerstone of vaccine design, immune memory serves a significant role in the host's defense against Plasmodium infections. It has long been considered that innate imm...
Source: Cancer Control - February 7, 2023 Category: Cancer & Oncology Authors: Jin-Guang Chen Yun-Ting Du Chang-Hui Guan Hua-Yu Fan Yang-Ai Liu Ting Wang Xin Li Guang Chen Source Type: research
Viruses to rescue health: Vaccination
Med Sci (Paris). 2022 Dec;38(12):1052-1060. doi: 10.1051/medsci/2022168. Epub 2022 Dec 13.ABSTRACTViruses have been used as tools to prevent viral infections themselves for more than two centuries with impressive success. After the empirical discoveries of the first vaccines, today the development of genetic engineering, molecular virology, reverse genetics, the manipulation of viral genomes, their high-throughput sequencing and their chemical synthesis, the mastery of cell culture and purification methods have greatly benefited the development of viral vaccines. Since smallpox and rabies, the history of vaccinology has fo...
Source: Cancer Control - January 24, 2023 Category: Cancer & Oncology Authors: Fr édéric Tangy Jean-Nicolas Tournier Source Type: research
Human IL-10-producing Th1 cells exhibit a molecular signature distinct from Tr1 cells in malaria
J Clin Invest. 2023 Jan 3;133(1):e153733. doi: 10.1172/JCI153733.ABSTRACTControl of intracellular parasites responsible for malaria requires host IFN-γ+T-bet+CD4+ T cells (Th1 cells) with IL-10 produced by Th1 cells to mitigate the pathology induced by this inflammatory response. However, these IL-10-producing Th1 (induced type I regulatory [Tr1]) cells can also promote parasite persistence or impair immunity to reinfection or vaccination. Here, we identified molecular and phenotypic signatures that distinguished IL-10-Th1 cells from IL-10+Tr1 cells in Plasmodium falciparum-infected people who participated in controlled h...
Source: Cancer Control - January 3, 2023 Category: Cancer & Oncology Authors: Chelsea L Edwards Susanna S Ng Fabian de Labastida Rivera Dillon Corvino Jessica A Engel Marcela Montes de Oca Luzia Bukali Teija Cm Frame Patrick T Bunn Shashi Bhushan Chauhan Siddharth Sankar Singh Yulin Wang Jinrui Na Fiona H Amante Jessica R Loughland Source Type: research
The COVID-19 pandemic and disruptions to essential health services in Kenya: a retrospective time-series analysis
Lancet Glob Health. 2022 Sep;10(9):e1257-e1267. doi: 10.1016/S2214-109X(22)00285-6.ABSTRACTBACKGROUND: Public health emergencies can disrupt the provision of and access to essential health-care services, exacerbating health crises. We aimed to assess the effect of the COVID-19 pandemic on essential health-care services in Kenya.METHODS: Using county-level data routinely collected from the health information system from health facilities across the country, we used a robust mixed-effect model to examine changes in 17 indicators of essential health services across four periods: the pre-pandemic period (from January, 2018 to ...
Source: Cancer Control - August 12, 2022 Category: Cancer & Oncology Authors: Helen Kiarie Marleen Temmerman Mutono Nyamai Nzisa Liku Wangari Thuo Violet Oramisi Lilly Nyaga Janette Karimi Phidelis Wamalwa Gladwell Gatheca Valerian Mwenda Loice Achieng Ombajo S M Thumbi Essential Health Services Data Monitoring and Evaluation sub-w Source Type: research
Nucleic Acid-based Immuno-prophylaxis and -therapies against Tropical Diseases
Yakugaku Zasshi. 2022;142(7):709-713. doi: 10.1248/yakushi.21-00210-5.ABSTRACTThe number of clinical trials investigating the use of nucleic acid drugs, including DNA/RNA-based vaccines, immunostimulatory/modulatory DNA/RNA and cyclic dinucleotides, for immuno-prophylaxis and -therapy has been increasing exponentially in recent years. These new drugs have revealed their therapeutic potential not only as vaccines or adjuvant therapies, but also as monotherapies for use in immuno-therapy of cancer and allergic disease. I will present an overview of their current R&D taking place in this field, then describe our recent pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - July 5, 2022 Category: Drugs & Pharmacology Authors: Ken J Ishii Source Type: research
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment
Vaccine. 2022 Jun 14:S0264-410X(22)00755-1. doi: 10.1016/j.vaccine.2022.06.008. Online ahead of print.ABSTRACTReplication-deficient adenoviral vectors have been under investigation as a platform technology for vaccine development for several years and have recently been successfully deployed as an effective COVID-19 counter measure. A replication-deficient adenoviral vector based on the simian adenovirus type Y25 and named ChAdOx1 has been evaluated in several clinical trials since 2012. The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) was formed to evaluate the safety and other key fe...
Source: Vaccine - June 17, 2022 Category: Allergy & Immunology Authors: Pedro M Folegatti Daniel Jenkin Susan Morris Sarah Gilbert Denny Kim James S Robertson Emily R Smith Emalee Martin Marc Gurwith Robert T Chen Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO, ex-V3SWG) Source Type: research
Travel vaccines are strongly associated to reduced mortality in prostate cancer patients - a real effect or residual confounding?
Vaccine. 2022 May 21:S0264-410X(22)00611-9. doi: 10.1016/j.vaccine.2022.05.028. Online ahead of print.ABSTRACTRepurposing of existing drugs and vaccines for diseases that they were not originally intended for is a promising research field. Recently there has been evidence that oral cholera vaccine might be used in the treatment of inflammatory disease and some common cancers. Specifically, Ji et al showed that the administration of cholera vaccine after a prostate cancer diagnosis reduced prostate cancer specific mortality rates by almost 50%. In a cohort of men from Stockholm, Sweden, with more detailed cancer data and a ...
Source: Vaccine - May 24, 2022 Category: Allergy & Immunology Authors: Axel M öller Klaus Schwamborn Adrian Spillmann Janet Hoogstraate Robert Szulkin Olof Akre Lars Egevad Mark Clements Markus Aly Source Type: research
